It’s Almost Time: See Why Aprea Therapeutics (Nasdaq: APRE) Is Topping Our Watchlist This Morning

*Sponsored Market Crux Announces Aprea Therapeutics, Inc. (Nasdaq: APRE) As Our Next Potential Breakout Idea! And Here’s Why… Analyst Coverage: HC Wainwright & Co. And Maxim Group Set $20 And $16 Targets For (APRE), Suggesting 400% And 300% Upside Potential. Limited Float: (APRE) Has A Market Cap Under $22M And Fewer Than 4M Shares In The Float, Offering Significant Growth Potential. Strong Fiscal Position: (APRE) Holds $22.8M In Ca-sh And Equivalents, Plus An Additional $18M Potential From Warrant Exercises. Disruptive Cancer Research: (APRE) Is Pioneering ATRN-119 And APR-1051, Therapies Targeting DDR-Related Mutations To Redefine Cancer Treatment. First-In-Class Molecule: ATRN-119 Is The First Macrocyclic ATR Inhibitor In Clinical Trials, Offering Selectivity And Potency Over Older Treatments. Promising Clinical Data: ATRN-119 Shows Strong Tumor Control, While APR-1051 Demonstrates Anti-Tumor Activity With Minimal Side Effects. Consider Taking a Look at Aprea Therapeutics, Inc. (Nasdaq: APRE) Before This Morning's Bell Rings… February 5, 2025 Dear Reader, It’s almost time. Have you considered taking a look at Aprea Therapeutics, Inc. (Nasdaq: APRE) this morning?  We have less than 15 minutes to go before the bell rings. Few sectors hold as much untapped potential as biotechnology, where one groundbreaking discovery can transform an obscure company into a powerhouse in no time. When a firm pushes the limits of science with revolutionary advancements, the market reacts swiftly—no one can ignore it. Yet, there are certain breakthroughs that don’t merely shift the needle—they redefine the entire landscape. One such company leading the charge is Aprea Therapeutics, Inc. (Nasdaq: APRE), a company at the forefront of precision oncology, whose cutting-edge research in synthetic lethality has the potential to dramatically alter the way we fight cancer.  But don’t just take our word for it—Benzinga reported on 1/15/2025 that HC Wainwright & Co., one of the country's oldest and most trusted institutions, recently reiterated a $20 target on (APRE), suggesting over 400% upside potential from Friday’s close of $3.91. And they’re not the only ones. Just weeks later, on 1/31/2025, Maxim Group also reiterated a $16 target, signaling over 300% upside from the same close. While large-cap companies may dominate the headlines, it’s often the small and micro-caps that offer the greatest growth potential.  With leaner operations, smaller revenue bases, and the ability to pivot quickly, these companies can scale rapidly when the right catalyst hits. Take Aprea Therapeutics, Inc. (Nasdaq: APRE)—with a market cap under $22M and fewer than 4M shares in the float, this is a company operating with the kind of tight structure that has historically fueled explosive growth potential. Keep reading to see why Aprea Therapeutics, Inc. (Nasdaq: APRE) is topping our watchlist this morning… Aprea Therapeutics, Inc. (Nasdaq: APRE): A Game-Changer  in Precision Oncology Let’s cut straight to the chase: Aprea Therapeutics, Inc. (Nasdaq: APRE) is not just another biotech company playing catch-up in the crowded oncology space.  They're rewriting the playbook, taking aim at some of the most stubborn cancers with innovative therapies that may just be a game-changer.  If you're looking to back a company that’s poised to make waves, this is it. Let's dive in. What Exactly Is Aprea Doing? Aprea Therapeutics is in the business of precision oncology, and not in the "here’s a generic treatment" way. They’re pioneers in a groundbreaking concept called synthetic lethality. This isn’t just some buzzword thrown around by your typical biotech firm; this is a targeted approach that could actually make cancer treatments more effective and less toxic. Their mission? To stop tumors in their tracks by exploiting the very weaknesses in cancer cells that make them so dangerous. They’re going after two major targets in the DNA Damage Response (DDR) system: ATR and WEE1. These are not your everyday targets—these are the type of molecules that could make or break the future of cancer treatments. Aprea Therapeutics, Inc. (Nasdaq: APRE)’s Precision Oncology: Two Inhibitors That Could Tackle Cancer with Unmatched Efficacy Aprea Therapeutics, Inc. (Nasdaq: APRE) is leading the charge with two potentially best-in-class inhibitors that have the potential to disrupt cancer care in a major way. ATRN-119: This is Aprea’s macrocyclic ATR inhibitor, and let me tell you, it’s unique. Unlike first-generation ATR inhibitors that have some serious toxicity and intermittent dosing schedules, ATRN-119 is engineered to be selective and highly potent. What does this mean for patients? Less toxicity, more effective continuous dosing, and a smoother treatment process. It’s been showing strong tumor control in preclinical studies, including in some of the most challenging genetic backgrounds. APR-1051: If you’ve been paying attention to the oncology world, you’ve probably heard of WEE1 inhibitors. But none like APR-1051. This inhibitor is structurally differentiated and exhibits high selectivity. Unlike others that wreak havoc on multiple systems (cue the toxic side effects), APR-1051 zeroes in on its target, leaving healthy cells largely unaffected. Early studies? Tumor suppression without the typical hematologic (blood-related) toxicity. This one’s got potentially compelling anti-tumor activity, especially in cancers with CCNE1 amplification—that’s ovarian cancer for those keeping score. Aprea Therapeutics, Inc. (Nasdaq: APRE) - Bold Moves in Cancer Treatment (APRE) is advancing rapidly with its approach to cancer treatment, and they’re showing no signs of slowing down.  In a recent announcement, the company unveiled a strategic shift in its ABOYA-119 clinical trial, now introducing a twice-daily (BID) dosing regimen for ATRN-119, its first-in-class macrocyclic ATR inhibitor The decision is based on solid scientific evidence suggesting that more frequent dosing will help maintain optimal therapeutic levels, ensuring greater activity across a 24-hour period. The first patient has already begun the 550 mg BID dose, marking a new phase in the trial. This adjustment is designed to optimize clinical outcomes and position ATRN-119 for accelerated regulatory pathways and commercial traction.  What sets (APRE) apart is that ATRN-119 is currently the only ATR inhibitor being tested as a continuous BID regimen, potentially putting it in a class of its own. Aprea Therapeutics, Inc. (Nasdaq: APRE) is doubling down on innovation and shaping the future of cancer care by targeting DDR-related mutations, a patient population that currently has limited treatment options.  With key milestones approaching, (APRE) is gearing up to make a serious impact in the oncology landscape. Why It Matters Aprea Therapeutics, Inc. (Nasdaq: APRE) is not just experimenting in the lab; they’re advancing rapidly. With a strong pipeline, the company is on track to move APR-1051 and ATRN-119 through the clinical stages. Open-label data for APR-1051 is expected in H2 2025, and early indications for ATRN-119 are already showing promising signs of clinical benefit.  This is the kind of progress that grabs attention. Aprea Therapeutics, Inc. (Nasdaq: APRE) is focusing on high-value indications, such as ovarian, colorectal, prostate, and breast cancers, which are significant, underserved areas in the market. With best-in-class potential, these therapies have the chance to become standard treatments for years to come. The company's pipeline is deep and promising, laying the groundwork for sustained growth. The Leadership: A Winning Team Aprea Therapeutics, Inc. (Nasdaq: APRE)’s management team isn’t just a group of pharma execs—they’re pioneers in synthetic lethality and targeted therapies. This is a team with cutting-edge expertise, not only in science but also in bringing their innovations to the market. Intellectual Property and Fiscal Position Aprea Therapeutics, Inc. (Nasdaq: APRE)’s got a solid foundation with its intellectual property, holding multiple U.S. patents protecting their ATR and WEE1 inhibitors, ensuring their work stays ahead of the competition.  Fiscally, (APRE) is well-positioned, with $22.8M in ca-sh & equivalents and the potential for an additional $18M from warrant exercises. With strong funding and partnerships in place, the company is poised to advance its pipeline and make significant strides in the oncology field. Aprea Therapeutics, Inc. (Nasdaq: APRE): A Company to Keep an Eye On as Cancer Treatment Evolves in 2025… So, here’s the deal. Aprea Therapeutics, Inc. (Nasdaq: APRE) isn’t just another biotech company hoping for a miracle.  They’re innovating at the highest level, developing therapies with the potential to truly change the cancer treatment landscape.  And with a team of experts leading the charge, strong intellectual property, and clinical milestones in sight, (APRE) is one to watch in 2025 and beyond. If you’re looking to get ahead of the curve in the world of precision oncology, (APRE) is a company you’ll want to keep an eye on.  7 Reasons Why Aprea Therapeutics, Inc. (Nasdaq: APRE) is Topping Our Watchlist This Morning… 1. Analyst Coverage: HC Wainwright & Co. and Maxim Group have set $20 and $16 targets for (APRE), suggesting upside potential of 400% and 300% from its recent close, respectively. 2. Limited Float: With a market cap under $22M & equivalents and fewer than 4M shares in the float, (APRE) is a small-cap company that could see significant growth if its treatments move forward as planned. 3. Strong Fiscal Position: (APRE) holds $22.8M in ca-sh & equivalents, plus the potential for an additional $18M from warrant exercises, providing the fiscal strength to advance its innovative pipeline. 4. Disruptive Cancer Research: (APRE) is pioneering ATRN-119 and APR-1051, two promising therapies targeting DDR-related mutations, which could redefine cancer treatment and tackle some of the most challenging cancers. 5. Innovative Dosing Strategy: The recent move to a twice-daily dosing regimen for ATRN-119 could optimize its efficacy, making it a strong contender in clinical trials and ahead of other therapies in development. 6. First-in-Class Molecule: ATRN-119 is the first macrocyclic ATR inhibitor in clinical trials, offering selectivity and potency—a key advantage over older, more toxic treatments. 7. Promising Clinical Data: Preclinical studies show ATRN-119 demonstrating strong tumor control, while APR-1051 is showing anti-tumor activity with minimal side effects, especially in difficult-to-treat cancers like ovarian cancer. Consider Adding Aprea Therapeutics, Inc. (Nasdaq: APRE) To Your Radar This Week… Aprea Therapeutics, Inc. (Nasdaq: APRE) is a little-known company with strong upside potential, as indicated by analyst targets from HC Wainwright & Co. ($20) and Maxim Group ($16), suggesting 400% and 300% upside, respectively. With a market cap under $22M and fewer than 4M shares in the float, (APRE) has significant growth potential, especially given its $22.8M in ca-sh. The company is leading the way with ATRN-119 and APR-1051, two innovative therapies targeting DDR-related mutations that could revolutionize cancer treatment. The shift to a twice-daily dosing regimen for ATRN-119 enhances its efficacy, while its first-in-class status and promising preclinical data give (APRE) a competitive edge in oncology. We’ve got (APRE) in our sights—and it’s topping our pre-market watchlist this morning. Consider taking a look at (APRE) before the bell rings. Also, keep an eye on your inbox and mobile device because my next update could be out any time this morning. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: marketcrux.com/disclaimer/  *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 02/04/2025 and ending on 02/05/2025 to publicly disseminate information about (APRE:US) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the funds from the issuer and does not own stock in the issuer but the reader should assume that the clients of the third party own shares in the issuer that they will liquidate at or near the time you receive this communication, which has the potential to hurt share prices. Neither Headline Media LLC, TD Media LLC or their members own shares of (APRE:US). Please see important disclosure information here: https://marketcrux.com/disclosure/apre/#details

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice